Publications:  Dr Daniela Loessner

Wagner F, Holzapfel BM, Martine LC, McGovern J, Lahr CA, Boxberg M, Prodinger PM, Grässel S et al.(2019). A humanized bone microenvironment uncovers HIF2 alpha as a latent marker for osteosarcoma. Acta Biomater vol. 89, 372-381.

Loessner D, Rockstroh A, Shokoohmand A, Holzapfel BM, Wagner F, Baldwin J, Boxberg M, Schmalfeldt B et al.(2019). A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns. Biomaterials vol. 190-191, 63-75.

McGovern JA, Shafiee A, Wagner F, Lahr CA, Landgraf M, Meinert C, Williams ED, Russell PJ et al.(2018). Humanization of the Prostate Microenvironment Reduces Homing of PC3 Prostate Cancer Cells to Human Tissue-Engineered Bone. Cancers (Basel) vol. 10, (11)

Little JP, Pettet GJ, Hutmacher DW, Loessner D(2018). SpheroidSim-Preliminary evaluation of a new computational tool to predict the influence of cell cycle time and phase fraction on spheroid growth. Biotechnol Prog vol. 34, (6) 1335-1343.

Wang P, Magdolen V, Seidl C, Dorn J, Drecoll E, Kotzsch M, Yang F, Schmitt M et al.(2018). Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer. Br J Cancer vol. 119, (7) 1-9.

Loessner D, Goettig P, Preis S, Felber J, Bronger H, Clements JA, Dorn J, Magdolen V(2018). Kallikrein-related peptidases represent attractive therapeutic targets for ovarian cancer. Expert Opin Ther Targets vol. 22, (9) 745-763.

Wagner F, Holzapfel BM, McGovern JA, Shafiee A, Baldwin JG, Martine LC, Lahr CA, Wunner FM et al.(2018). Humanization of bone and bone marrow in an orthotopic site reveals new potential therapeutic targets in osteosarcoma. Biomaterials vol. 171, 230-246.

Quent V, Taubenberger AV, Reichert JC, Martine LC, Clements JA, Hutmacher DW, Loessner D(2018). A humanised tissue-engineered bone model allows species-specific breast cancer-related bone metastasis in vivo. J Tissue Eng Regen Med vol. 12, (2) 494-504.

Meinert C, Theodoropoulos C, Klein TJ, Hutmacher DW, Loessner D(2018). A Method for Prostate and Breast Cancer Cell Spheroid Cultures Using Gelatin Methacryloyl-Based Hydrogels. Methods Mol Biol vol. 1786, 175-194.

Momot KI, Bas O, Holzapfel NP, Loessner D(2017). Magnetic resonance microimaging of cancer cell spheroid constructs. Biomedical Spectroscopy and Imaging vol. 5, (1) 41-54.

Holzapfel NP, Shokoohmand A, Wagner F, Landgraf M, Champ S, Holzapfel BM, Clements JA, Hutmacher DW et al.(2017). Lycopene reduces ovarian tumor growth and intraperitoneal metastatic load. Am J Cancer Res vol. 7, (6) 1322-1336.

Muerza-Cascante ML, Shokoohmand A, Khosrotehrani K, Haylock D, Dalton PD, Hutmacher DW, Loessner D(2017). Endosteal-like extracellular matrix expression on melt electrospun written scaffolds. Acta Biomater vol. 52, 145-158.

Tourell MC, Shokoohmand A, Landgraf M, Holzapfel NP, Poh PSP, Loessner D, Momot KI(2017). The distribution of the apparent diffusion coefficient as an indicator of the response to chemotherapeutics in ovarian tumour xenografts. Sci Rep vol. 7,

Fuhrman-Luck RA, Stansfield SH, Stephens CR, Loessner D, Clements JA(2016). Prostate Cancer-Associated Kallikrein-Related Peptidase 4 Activates Matrix Metalloproteinase-1 and Thrombospondin-1. J Proteome Res vol. 15, (8) 2466-2478.

Fuhrman-Luck R, Hastie M, Ho B, Stoll T, Stephens C, Kryza T, Rockstroh A, Lehman M et al. (2016). Use multi-omics platforms for comprehensive assessment of the mechanism of action of kallikreinrelated peptidase 4 (KLK4) in the prostate tumour microenvironment. BJU INTERNATIONAL. Conference: Asia-Pacific Prostate Cancer Conference vol. 118, 28-28.

Wagner F, Holzapfel BM, Thibaudeau L, Straub M, Ling M-T, Grifka J, Loessner D, Lévesque J-P et al.(2016). A Validated Preclinical Animal Model for Primary Bone Tumor Research. J Bone Joint Surg Am vol. 98, (11) 916-925.

Badenoch-Jones EK, Lynham AJ, Loessner D(2016). Consent for third molar tooth extractions in Australia and New Zealand: a review of current practice. Aust Dent J vol. 61, (2) 203-207.

Loessner D, Meinert C, Kaemmerer E, Martine LC, Yue K, Levett PA, Klein TJ, Melchels FPW et al.(2016). Functionalization, preparation and use of cell-laden gelatin methacryloyl-based hydrogels as modular tissue culture platforms. Nat Protoc vol. 11, (4) 727-746.

Kryza T, Silva ML, Loessner D, Heuzé-Vourc'h N, Clements JA(2016). The kallikrein-related peptidase family: Dysregulation and functions during cancer progression. Biochimie vol. 122, 283-299.

Dorn J, Yassouridis A, Walch A, Diamandis EP, Schmitt M, Kiechle M, Wang P, Drecoll E et al.(2016). Assessment of kallikrein-related peptidase 5 (KLK5) protein expression in tumor tissue of advanced ovarian cancer patients by immunohistochemistry and ELISA: correlation with clinical outcome. Am J Cancer Res vol. 6, (1) 61-70.

Holzapfel NP, Holzapfel BM, Theodoropoulos C, Kaemmerer E, Rausch T, Feldthusen J, Champ S, Clements JA et al.(2016). Lycopene's Effects on Cancer Cell Functions within Monolayer and Spheroid Cultures. Nutr Cancer vol. 68, (2) 350-363.

Hutmacher DW, Holzapfel BM, De-Juan-Pardo EM, Pereira BA, Ellem SJ, Loessner D, Risbridger GP(2015). Convergence of regenerative medicine and synthetic biology to develop standardized and validated models of human diseases with clinical relevance. Curr Opin Biotechnol vol. 35, 127-132.

Badenoch-Jones E, Lynham A(2015). Consent for third molar tooth extractions in Australia and New Zealand: a review of current practice. International Journal of Oral and Maxillofacial Surgery vol. 44, e32-e32.

Bock N, Loessner D, Clements JA, Hutmacher DW (2015). A Tissue Engineered Bone Construct as a 3D Metastasis Colonization Model. TISSUE ENGINEERING PART A. vol. 21, S277-S277.

Loessner D, Holzapfel BM, Clements JA, Hutmacher DW (2015). Design of Disease Models using Tissue Engineering Principles. TISSUE ENGINEERING PART A. vol. 21, S189-S189.

Bock N, Loessner D, Hutmacher D, Clements J (2015). A 3D in vitro model reflecting the androgen deprivation state in prostate cancer bone metastasis. BJU INTERNATIONAL. vol. 116, 38-38.

Fuhrman-Luck R, Kryza T, Hastie M, Stoll T, Kleifeld O, Ho B, Lehman M, Rockstroh A et al. (2015). Kallikrein-related peptidase 4 induces tumour microenvironment alterations that support tumour growth. BJU INTERNATIONAL. vol. 116, 38-38.

Holzapfel BM, Hutmacher DW, Nowlan B, Barbier V, Thibaudeau L, Theodoropoulos C, Hooper JD, Loessner D et al.(2015). Tissue engineered humanized bone supports human hematopoiesis in vivo. Biomaterials vol. 61, 103-114.

Hutmacher DW, Little JP, Pettet GJ, Loessner D(2015). Biomaterial science meets computational biology. J Mater Sci Mater Med vol. 26, (5)

Loessner D, Rizzi SC, Stok KS, Magdolen V, Hutmacher DW, Clements JA (2015). An engineered tumour microenvironment provides new insights into cancer progression and drug responses. CLINICAL & EXPERIMENTAL METASTASIS. vol. 32, 220-220.

Fuhrman-Luck R, Stansfield S, Hastie M, Stoll T, Stephens C, Loessner D, Lehman M, Nelson C et al. (2015). The Kallikrein-related serine peptidase, KLK4, regulates the TGF beta 1 pathway in the tumour-stroma microenvironment in prostate cancer. CLINICAL & EXPERIMENTAL METASTASIS. vol. 32, 197-197.

Loessner D, Holzapfel BM, Clements JA(2014). Engineered microenvironments provide new insights into ovarian and prostate cancer progression and drug responses. Adv Drug Deliv Rev vol. 79-80, 193-213.

Fuhrman-Luck RA, Loessner D, Clements JA(2014). Kallikrein-Related Peptidases in Prostate Cancer: From Molecular Function to Clinical Application. EJIFCC vol. 25, (3) 269-281.

Bonda UH, Bray LJ, Lister N, Ellem S, Risbridger G, Freudenberg U, Werner CC, Hutmacher DW et al. (2014). Mimicking the tumour microenvironment (TME): Angiogenesis in tumour progression. EUROPEAN JOURNAL OF CANCER. vol. 50, S62-S62.

Clements J, Fuhrman-Luck R, Stansfield S, Hastie M, Stoll T, Stephens C, Loessner D, Lehman M et al. (2014). The kallikrein-related serine peptidase, KLK4, regulates the TGF beta 1 pathway in the tumour-stroma microenvironment in prostate cancer. EUROPEAN JOURNAL OF CANCER. vol. 50, S65-S66.

Loessner D, Holzapfel BM, Baldwin J, Rockstroh A, Magdolen V, Hutmacher DW, Clements JA (2014). The tumour-stroma niche of ovarian cancer in 3D. EUROPEAN JOURNAL OF CANCER. vol. 50, S24-S24.

Loessner D, Holzapfel BM, Baldwin J, Rockstroh A, Magdolen V, Clements JA, Hutmacher DW (2014). An engineered tumour-stroma niche provides new insights into disease progression. JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE. vol. 8, 314-315.

Kaemmerer E, Melchels FPW, Holzapfel BM, Meckel T, Hutmacher DW, Loessner D(2014). Gelatine methacrylamide-based hydrogels: an alternative three-dimensional cancer cell culture system. Acta Biomater vol. 10, (6) 2551-2562.

Fuhrman-Luck RA, Silva ML, Dong Y, Irving-Rodgers H, Stoll T, Hastie ML, Loessner D, Gorman JJ et al.(2014). Proteomic and other analyses to determine the functional consequences of deregulated kallikrein-related peptidase (KLK) expression in prostate and ovarian cancer. Proteomics Clin Appl vol. 8, (5-6) 403-415.

Holzapfel BM, Wagner F, Loessner D, Holzapfel NP, Thibaudeau L, Crawford R, Ling M-T, Clements JA et al.(2014). Species-specific homing mechanisms of human prostate cancer metastasis in tissue engineered bone. Biomaterials vol. 35, (13) 4108-4115.

Shahinian H, Loessner D, Biniossek ML, Kizhakkedathu JN, Clements JA, Magdolen V, Schilling O(2014). Secretome and degradome profiling shows that Kallikrein-related peptidases 4, 5, 6, and 7 induce TGFβ-1 signaling in ovarian cancer cells. Mol Oncol vol. 8, (1) 68-82.

Dong Y, Loessner D, Irving-Rodgers H, Obermair A, Nicklin JL, Clements JA(2014). Metastasis of ovarian cancer is mediated by kallikrein related peptidases. Clin Exp Metastasis vol. 31, (1) 135-147.

Loessner D, Rizzi SC, Stok KS, Fuehrmann T, Hollier B, Magdolen V, Hutmacher DW, Clements JA(2013). A bioengineered 3D ovarian cancer model for the assessment of peptidase-mediated enhancement of spheroid growth and intraperitoneal spread. Biomaterials vol. 34, (30) 7389-7400.

Loessner D, Rizzi SC, Stok KS, Magdolen V, Hutmacher DW, Clements JA (2013). A bioengineered ovarian cancer microenvironment to assess protease-associated functions. CLINICAL CANCER RESEARCH. vol. 19,

Fuhrman-Luck R, Kleifeld O, Ho B, Hastie M, Stoll T, Stephens C, Loessner D, Stansfield S et al. (2013). KALLIKREIN-RELATED PEPTIDASE 4 IS A KEY REGULATOR OF THE PROSTATE CANCER MICROENVIRONMENT. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY. vol. 40, 14-14.

Loessner D, Kobel S, Clements JA, Lutolf MP, Hutmacher DW(2013). Hydrogel Microwell Arrays Allow the Assessment of Protease-Associated Enhancement of Cancer Cell Aggregation and Survival. Microarrays (Basel) vol. 2, (3) 208-227.

Fuhrman-Luck R, Hastie M, Stansfield S, Stoll T, Rockstroh A, Lehman M, Nelson C, Loessner D et al. (2013). Kallikrein-related peptidase 4initiates tumour-stroma cross-talk in prostate cancer. BJU INTERNATIONAL. vol. 112, 44-45.

Loessner D, Little JP, Pettet GJ, Hutmacher DW(2013). A multiscale road map of cancer spheroids--incorporating experimental and mathematical modelling to understand cancer progression. J Cell Sci vol. 126, (Pt 13) 2761-2771.

LOESSNER D(2013). Integrin-functionalized artificial membranes as test platforms for monitoring small integrin ligand binding by surface plasmon-enhanced fluorescence spectroscopy. Handbook of Biofunctional Surfaces, CRC Press

Loessner D, Flegg JA, Byrne HM, Clements JA, Hutmacher DW(2013). Growth of confined cancer spheroids: a combined experimental and mathematical modelling approach. Integr Biol (Camb) vol. 5, (3) 597-605.

Dong Y, Loessner D, Sieh S, Taubenberger A, Fuhrman-Luck RA, Magdolen V, Hutmacher DW, Clements JA(2012). Cellular model systems to study the tumor biological role of kallikrein-related peptidases in ovarian and prostate cancer. Novel cancer-related biomarkers,

Loessner D, Quent VMC, Kraemer J, Weber EC, Hutmacher DW, Magdolen V, Clements JA(2012). Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance. Gynecol Oncol vol. 127, (3) 569-578.

Brown TD, Slotosch A, Thibaudeau L, Taubenberger A, Loessner D, Vaquette C, Dalton PD, Hutmacher DW(2012). Design and fabrication of tubular scaffolds via direct writing in a melt electrospinning mode. Biointerphases vol. 7, (1-4)

Loessner D, Baldwin J, Rockstroh A, Irving-Rodgers H, Magdolen V, Hutmacher DW, Clements JA (2012). 3D bioengineered model of the tumor-stroma microenvironment of late stage ovarian cancer. JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE. vol. 6, 348-348.

Fuhrman-Luck R, Stansfield S, Stephens C, Loessner D, Clements J (2012). Kallikrein-related Peptidase 4 and Prostate Cancer - an Extended Role in Tumour Progression. EUROPEAN JOURNAL OF CANCER. vol. 48, S61-S61.

Loessner D, Baldwin J, Rockstroh A, Irving-Rodgers H, Magdolen V, Hutmacher DW, Clements JA (2012). Unravelling the Tumour-stroma Microenvironment of Late Stage Ovarian Cancer. EUROPEAN JOURNAL OF CANCER. vol. 48, S28-S28.

Brown TD, Slotosch A, Thibaudeau L, Taubenberger A, Loessner D, Vaquette C, Dalton PD, Hutmacher DW(2012). Design and fabrication of tubular scaffolds via direct writing in a melt electrospinning mode. Biointerphases vol. 7, (1-4) 1-16.

Lawrence MG, Margaryan NV, Loessner D, Collins A, Kerr KM, Turner M, Seftor EA, Stephens CR et al.(2011). Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells. Prostate vol. 71, (11) 1198-1209.

Loessner D, Stok KS, Lutolf MP, Hutmacher DW, Clements JA, Rizzi SC(2010). Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials vol. 31, (32) 8494-8506.

Quent VMC, Loessner D, Friis T, Reichert JC, Hutmacher DW(2010). Discrepancies between metabolic activity and DNA content as tool to assess cell proliferation in cancer research. J Cell Mol Med vol. 14, (4) 1003-1013.

Dong Y, Tan OL, Loessner D, Stephens C, Walpole C, Boyle GM, Parsons PG, Clements JA(2010). Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma. Cancer Res vol. 70, (7) 2624-2633.

Hutmacher DW, Loessner D, Rizzi S, Kaplan DL, Mooney DJ, Clements JA(2010). Can tissue engineering concepts advance tumor biology research?. Trends Biotechnol vol. 28, (3) 125-133.

Lössner D, Abou-Ajram C, Benge A, Aumercier M, Schmitt M, Reuning U(2009). Integrin αvβ3 upregulates integrin-linked kinase expression in human ovarian cancer cells via enhancement of ILK gene transcription. Journal of Cellular Physiology vol. 220, (2) 367-375.

Hutmacher DW, Horch RE, Loessner D, Rizzi S, Sieh S, Reichert JC, Clements JA, Beier JP et al.(2009). Translating tissue engineering technology platforms into cancer research. J Cell Mol Med vol. 13, (8A) 1417-1427.

Klein T, Schrobback K, Georgi N, Reichert J, Loessner D, Crawford R, Clements J, Hutmacher D (2008). Low-serum conditions for expansion culture of multiple cell types. TISSUE ENGINEERING PART A. vol. 14, 874-874.

Lössner D, Abou-Ajram C, Benge A, Reuning U(2008). Integrin αvβ3 mediates upregulation of epidermal growth-factor receptor expression and activity in human ovarian cancer cells. The International Journal of Biochemistry & Cell Biology vol. 40, (12) 2746-2761.

Lenski C, Kooy RF, Reyniers E, Loessner D, Wanders RJA, Winnepenninckx B, Hellebrand H, Engert S et al.(2007). The reduced expression of the HADH2 protein causes X-linked mental retardation, choreoathetosis, and abnormal behavior. Am J Hum Genet vol. 80, (2) 372-377.

Lössner D, Kessler H, Thumshirn G, Dahmen C, Wiltschi B, Tanaka M, Knoll W, Sinner E-K et al.(2006). Binding of Small Mono- and Oligomeric Integrin Ligands to Membrane-Embedded Integrins Monitored by Surface Plasmon-Enhanced Fluorescence Spectroscopy. Analytical Chemistry vol. 78, (13) 4524-4533.